EuMentis Therapeutics Inc
EuMentis Therapeutics Inc. is a privately held, clinical stage biotech company focused on the development of novel therapeutics to treat neuropsychiatric conditions with high unmet need. The Company’s lead product, EM-221, is a best-in-class, oral, PDE10A inhibitor designed to modulate the dopamine D2 pathway specifically in the striatum.